RxDoctor Payments Data

Catherine Stead

Family · Irving, TXNPI 1699294363

Payments from drug & device makers

$1,719in general payments, 2019–2025

Across 82 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$479
  • AbbVie$445
  • Astellas Pharma US Inc$301
  • Convatec Inc.$122
  • Medtronic$122
  • Urovant Sciences Inc$96
  • plus $154 from 6 others

What the payments were for

  • Food & beverage$1,63495%
  • Education$855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.31$479
AbbVie18$445
Astellas Pharma US Inc9$301
Convatec Inc.5$122
Medtronic5$122
Urovant Sciences Inc6$96
Axonics, Inc.2$43
Mimedx Group, Inc.1$27
Rochester Medical Corporation2$26
Pfizer1$24
Laborie Medical Technologies Corp.1$22
180 Medical, Inc.1$13

How this compares

$1,719 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$74,798
Medicare patients
254
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron86$69,937
GemtesaVibegron57$60,850
Fosfomycin Tromethamine34$10,513
Estradiol133$8,309
Mirabegron ErMirabegron13$7,878
EstringEstradiol14$7,040
Methenamine Hippurate64$5,836
Trospium Chloride29$1,616
Trimethoprim13$1,237
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst59$801
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav90$702
Cephalexin42$537
NitrofurantoinNitrofurantoin Macrocrystal14$445
Cefdinir26$415
Ciprofloxacin Hcl30$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$301$69,93786 claims
Sumitomo Pharma America, Inc.Gemtesa$479$60,85057 claims
PfizerEstring$24$7,04014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →